Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proposal for the delineation of neoadjuvant target volumes in oesophageal cancer.
Thomas M, Mortensen HR, Hoffmann L, Møller DS, Troost EGC, Muijs CT, Berbee M, Bütof R, Nicholas O, Radhakrishna G, Defraene G, Nafteux P, Nordsmark M, Haustermans K. Thomas M, et al. Among authors: radhakrishna g. Radiother Oncol. 2021 Mar;156:102-112. doi: 10.1016/j.radonc.2020.11.032. Epub 2020 Dec 5. Radiother Oncol. 2021. PMID: 33285194
Treatment planning comparison in the PROTECT-trial randomising proton versus photon beam therapy in oesophageal cancer: Results from eight European centres.
Hoffmann L, Mortensen H, Shamshad M, Berbee M, Bizzocchi N, Bütof R, Canters R, Defraene G, Ehmsen ML, Fiorini F, Haustermans K, Hulley R, Korevaar EW, Clarke M, Makocki S, Muijs CT, Murray L, Nicholas O, Nordsmark M, Radhakrishna G, Thomas M, Troost EGC, Vilches-Freixas G, Visser S, Weber DC, Møller DS. Hoffmann L, et al. Among authors: radhakrishna g. Radiother Oncol. 2022 Jul;172:32-41. doi: 10.1016/j.radonc.2022.04.029. Epub 2022 May 2. Radiother Oncol. 2022. PMID: 35513132 Free article. Clinical Trial.
Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.
Mortensen HR, Populaire P, Hoffmann L, Moeller DS, Appelt A, Nafteux P, Muijs CT, Grau C, Hawkins MA, Troost EGC, Defraene G, Canters R, Clarke CS, Weber DC, Korevaar EW, Haustermans K, Nordsmark M, Gebski V, Achiam MP, Markar SR, Radhakrishna G, Berbee M, Scartoni D, Orlandi E, Doyen J, Gregoire V, Crehange G, Langendijk J, Lorgelly P, Blommenstein HM, Byskov CS, Ehmsen ML, Jensen MF, Freixas GV, Bütof R; PROTECT consortium. Mortensen HR, et al. Among authors: radhakrishna g. Radiother Oncol. 2024 Jan;190:109980. doi: 10.1016/j.radonc.2023.109980. Epub 2023 Nov 5. Radiother Oncol. 2024. PMID: 37935284 No abstract available.
A treatment planning comparison of photon stereotactic ablative radiotherapy and proton beam therapy for the re-irradiation of pelvic cancer recurrence.
Chuter R, Glassborow E, Speight R, Clarke M, Murray L, Radhakrishna G, Lavin V, Aspin L, Aldred M, Gregory S, Richardson J, Handley J. Chuter R, et al. Among authors: radhakrishna g. Phys Imaging Radiat Oncol. 2022 Feb 23;21:78-83. doi: 10.1016/j.phro.2022.02.010. eCollection 2022 Jan. Phys Imaging Radiat Oncol. 2022. PMID: 35243036 Free PMC article.
Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study.
Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM. Rembielak AI, et al. Among authors: radhakrishna g. Transl Oncol. 2014 Feb 1;7(1):55-64. doi: 10.1593/tlo.13724. eCollection 2014 Feb. Transl Oncol. 2014. PMID: 24772208 Free PMC article.
An introduction to proton beam therapy.
Barker C, Lowe M, Radhakrishna G. Barker C, et al. Among authors: radhakrishna g. Br J Hosp Med (Lond). 2019 Oct 2;80(10):574-578. doi: 10.12968/hmed.2019.80.10.574. Br J Hosp Med (Lond). 2019. PMID: 31589515 Review.
79 results